Floatz logo

FAZA

Lung Neoplasm

AHS Cancer Control AlbertaSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

52 Active assets in the Lung Neoplasm cohort.

Asset / SponsorPhaseRating
Carboplatin
Nanfang Hospital, Southern Medical University
Phase 4BB
Nivolumab
Hospital Israelita Albert Einstein
Phase 2BB
BELAGENPUMATUCEL-L (SK-LU-1)
NovaRx Corporation
Phase 3BB
Icotinib
Fuda Cancer Hospital, Guangzhou
Phase 4BB
Rivoceranib
Fuzhou General Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

FAZA is also rated in:

Breast NeoplasmDormant
CC
Indicative ·
44 / 100
View asset →
Neuroendocrine TumoursDormant
CC
Indicative ·
41 / 100
View asset →
Renal Cell CarcinomaDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →